New combo therapy shows promise for advanced kidney cancer
NCT ID NCT05363631
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests whether adding a supplement called Seleno-L methionine to the standard two-drug therapy (axitinib and pembrolizumab) is safe and works better for people with advanced clear cell kidney cancer. About 55 participants will receive the combination. The goal is to see if the supplement can reduce side effects and improve tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.